GENINCODE PLC (GENI) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the GENINCODE PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press end. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Matthew Walls, CEO. Good morning, sir. Good morning, Lily, and good morning all. So I'm I'm in the Cavendish offices in the city. Normally, I would be here alongside Paul Fulgier. But, unfortunately, Paul this morning getting into London. There's been a a problem on the on the line coming into Waterloo. He hasn't arrived into Waterloo yet. So he may or may not join us. But so in the meantime, it's it's just myself. So I'll I'll move through things as we typically do, probably at some pace. There's quite a number of slides to get through, and there's quite a lot of updating for the market. So let's move on. I'll pick up on the main headlines on the financial and final results from 2025. So that's year end in December 2025. We'll take a look at the business in terms of what's happening in prevention, changes more recently that have been announced, US strategy, EU, and UK, and then we'll finish on the financials and outlook. I won't go through the summary of the company. I'll assume that most investors are familiar with that. I will start here now. So this is the the progress update for the year ending December 25. Good growth, albeit I would have like...